21 research outputs found
Running title: Effects of milk on cytokine production Correspondence to:
Effects of breast milk from allergic and nonallergic mothers on mitogen- and allergeninduce
Immune responses to birch in young children during their first 7 years of life
Background The character of immune responses to allergens during the first years of life may decide whether the individual will become tolerant or develop allergy later in life. Objective To study the development of immune responses to the seasonal inhalant allergen birch over the first 7 years of life. Methods Blood samples were obtained from 21 children who were followed prospectively from the second to the seventh pollen season of life. Birch-induced cytokine production and IgG subclass antibodies to rBet v 1 were analysed with ELISA, mRNA expression with real time PCR, IgE antibodies to birch with Magic LiteTM and birch-induced mononuclear cell proliferation with 3H-thymidine incorporation. Results Birch-induced IFN-Ī³ and IL-10 production increased with age, both in atopic and non-atopic children, while birch-induced IL-13 production decreased. The two children who were sensitized and developed clinical allergy to birch showed persistent IL-4 and IL-5 production and IL-9 mRNA expression, as well as Th2-associated IgG4 responses. Transient Th2-like responses were observed among the other children. Proliferative responses and IgG1 antibodies were seen in all children. Conclusions Immune responses to birch can be demonstrated in all children, during the first 7 years of life, regardless of atopic status. A transient early Th2-like response is down-regulated after the fourth pollen season, except in children who develop clinical allergy to the particular allergen
The value of clinical and histopathological characteristics for the prognosis of malignant laryngeal tumours
Balsenes ļaundabÄ«gs audzÄjs ir otrais biežÄk sastopams elpoÅ”anas sistÄmas audzÄjs pÄc plauÅ”u audzÄja. TÄ ir viena no onkoloÄ£iskÄm slimÄ«bÄm, pie kuras pacientu kopÄjÄ dzÄ«vildze pÄdÄjo 20 gadu laikÄ ir samazinÄjusies no 66% lÄ«dz 63%. HistopatoloÄ£iskam slÄdzienam ir bÅ«tiska nozÄ«me balsenes ļaundabÄ«gÄ audzÄja ÄrstÄÅ”anas stratÄÄ£ijas izvÄlÄ un prognozes izvÄrtÄÅ”anÄ.PÄtÄ«juma mÄrÄ·is ir novÄrtÄt balsenes ļaundabÄ«gÄ audzÄja klÄ«nisko un histopatoloÄ£isko rÄdÄ«tÄju ietekmi uz recidÄ«va attÄ«stÄ«bu, pacienta kopÄjo un bezrecidÄ«va dzÄ«vildzi.PÄtÄ«jumÄ tika iekļauti 105 pacienti, kuriem histoloÄ£iski tika apstiprinÄta balsenes ļaundabÄ«gÄ audzÄja diagnoze. Tika analizÄti histopatoloÄ£iskie slÄdzieni no RAKUS PatoloÄ£ijas Centra arhÄ«va datubÄzes un klÄ«niskÄ informÄcija no āÄrsta birojaā datiem par 2011.gadu.Datu apstrÄde tika veikta ar Microsoft Office Excel 2013 un IBM SPSS Statistics 22 versiju. PÄtÄ«jumÄ iegÅ«tie rezultÄti parÄdÄ«ja, ka balsenes ļaundabÄ«gÄ audzÄja biežÄka histoloÄ£iskÄ forma bija plakanŔūnu karcinoma (n=104; 90,05%), kas pamatÄ bija vidÄji diferencÄta (n=65; 62,5%). BiežÄk tÄ bija sastopama vÄ«rieÅ”iem (n=101; 96,19%). Pacientu vidÄjais vecums bija 62,04 Ā± 10,02 gadi. BiežÄka lokalizÄcija bija glottis apvidÅ« (n=63; 60%). Galvenais no pirmajiem simptomiem pacientiem ar balsenes ļaundabÄ«go audzÄju bija balss piesmakums (n=66; 62,86%). LielÄkai daļai pacientu balsenes ļaundabÄ«gs audzÄjs bija diagnosticÄts vÄlÄ«ni, III stadijÄ (n=53; 53,54%). No mÅ«su pÄtÄ«jumÄ iekļautiem pacientiem recidÄ«vs attÄ«stÄ«jÄs 25 (24,04%) pacientiem, biežÄk tas bija novÄrojams pirmajos trijos gados kopÅ” diagnozes noteikÅ”anas brīža. Tika konstatÄts, ka recidÄ«va attÄ«stÄ«ba biežÄk raksturÄ«ga gados jaunÄkiem pacientiem (lÄ«dz 60 gadiem) (Rho=0.207; p=0.034) un pacientiem ar lielÄku T apakÅ”stadiju (Rho= -0.233; p=0.022). MÅ«su pÄtÄ«jumÄ tika konstatÄti pacientu bezrecidÄ«va dzÄ«vildzi un kopÄjo dzÄ«vildzi ietekmÄjoÅ”ie faktori. Galvenie bezrecidÄ«va dzÄ«vildzi ietekmÄjoÅ”ie faktori ir audzÄja stadija (p=0.032), Ä«paÅ”i T apakÅ”stadija (p=0.010) atbilstoÅ”i TNM klasifikÄcijai un audzÄja izplatÄ«ba uz hipofarinksu (p=0.009). SliktÄka bezrecidÄ«va dzÄ«vildze novÄrojama pacientiem ar III stadiju un lielÄku T apakÅ”stadiju. KopÄjo dzÄ«vildzi pacientiem ar balsenes ļaundabÄ«go audzÄju ietekmÄ pacientu dzimums (p=0.042), audzÄja diferenciÄcijas pakÄpe (p=0.010), audzÄja izplatÄ«ba uz hipofarinksu (p=0.009), metastÄžu esamÄ«ba (p=0.039) un T apakÅ”stadija (p=0.003). SliktÄka kopÄjÄ dzÄ«vildze novÄrojama vÄ«rieÅ”iem, pacientiem ar zemu vai vidÄji diferencÄtiem audzÄjiem, audzÄjiem ar izplatÄ«bu uz hipofarinksu, pacientiem ar reÄ£ionÄlÄm un distÄlÄm metastÄzÄm un lielaku T apakÅ”stadiju. SecinÄjumi. KlÄ«nisko un histopatoloÄ£isko rÄdÄ«tÄju novÄrtÄÅ”ana ir bÅ«tiska balsenes ļaundabÄ«gÄ audzÄja prognozes izvÄrtÄÅ”anai un recidÄ«va riska stratifikÄcijai.Malignant laryngeal tumour is the second most common tumour of the respiratory system after lung cancer.It is one of the oncological diseases, to which patientsā overall survival rate during last 20 years has decreased from 66% to 63%.Histopathological findings have an important role deciding treatment strategy and in evaluation of prognosis.The aim of the study was to evaluate the impact of clinical and histopathological characteristics on tumour relapse, patients overall and relapse-free survival.105 patients with a histologically confirmed diagnosis of malignant laryngeal tumour were enrolled into the study. Histopathological data were analysed from the Riga East university Hospital Centre of Pathology database and clinical information database āÄrsta birojsā. The results were statistically analysed by Microsoft Office Excel 2013 and IBM SPSS Statistics 22.Our results showed, that the most frequent histological type of laryngeal cancer was squamous cell carcinoma (n=104; 90,05%), which was mostly moderately differentiated (n=65; 62,5%). It was more common in men (n=101; 96,19%). Patientsā mean age was 62,04 Ā± 10,02 years. The most frequent location was glottis (n=63; 60%). One of the main symptoms was hoarseness (n=66; 62,86%). In most patients, tumour was diagnosed at stage III (n=53; 53,54%). Relapse developed in 25 (24,04%) patients from our group, more often in first three years from date of diagnosis. It was found that tumour relapse is associated with relatively younger patient age (below 60 years) (Rho=0.207; p=0.034) and higher T substage (Rho= -0.233; p=0.022). The histopathological and clinical characteristics which influence relapse-free and overall survival rate was observed. The main factors that influence relapse-free survival rate was tumour stage (p=0.032), especially T substage (p=0.010) according to TNM classification, and tumour spread to hypopharynx (p=0.009). Worse relapse-free survival was found to patients with stage III, high T substage. Overall survival rate was influenced by gender (p=0.042), the degree of differentiation (p=0.010), tumour spread to hypopharynx (p=0.009), presence of metastasis (p=0.039) and T substage (p=0.003). Worse overall survival rate was observed in males, patients with poorly and moderately differentiated tumours, tumours with spread to hypopharynx, patients with regional and distal metastasis and high T substage. Conclusions. Clinical and histopathological characteristics have an important role in the evaluation of prognosis and stratification of tumour relapse risk
Cytokine responses to allergens during the first two years of life in Estonian and Swedish children
N.B.: When citing this work, cite the original article. This is the pre-reviewed version of the following article
Correspondence to:
Slow salivary secretory IgA maturation may relate to low microbial pressure and allergic symptoms in sensitized childre
Endotoxin levels in Estonian and Swedish house dust and atopy in infancy
N.B.: When citing this work, cite the original article. This is the pre-reviewed version of the following article
Effectivity of Mepilex Lite dressing in limitating skin side effects in vulvar cancer radiotherapy
Bakalaura darba tÄma āMepilex Lite plÄkstera efektivitÄte vulvas vÄža staru terapijas Ädas blakÅu ierobežoÅ”anÄā. Darba ietvaros tika pÄtÄ«ts plÄkstera Mepilex Lite pielietojums jonizÄjoÅ”Ä starojuma izraisÄ«tÄ Ädas bojÄjuma ierobežoÅ”anÄ. Darbs veikts balstoties uz kvalitatÄ«vÄs pÄtniecÄ«bas modeļa, kÄ pÄtniecÄ«bas instruments tika izmantots novÄroÅ”anas protokols. PÄtÄ«jumÄ izvirzÄ«tais jautÄjums ā kÄda ir jonizÄjoÅ”Ä starojuma izraisÄ«to Ädas bojÄjumu atŔķirÄ«ba grupÄ, kur staru terapijas laikÄ tika lietots Mepilex Lite plÄksteris raduÅ”os komplikÄciju ÄrstÄÅ”anas nolÅ«kÄ un grupu, kas plÄksteri lieto profilakses nolÅ«kÄ. PÄtÄ«juma mÄrÄ·is ā novÄrtÄt plÄkstera Mepilex Lite efektivitÄti jonizÄjoÅ”Ä starojuma radÄ«tÄ Ädas bojÄjuma profilaksÄ pacientiem pie vulvas vÄža staru terapijas. Apkopojot pÄtÄ«juma rezultÄtus, var secinÄt, ka Mepilex Lite plÄkstera pielietoÅ”ana profilaktiskÄ nolÅ«kÄ pacientÄm, kurÄm tiek veikta vulvas vÄža staru terapija, attÄlina jonizÄjoÅ”Ä starojuma izraisÄ«to Ädas bojÄjumu.The topic of the present Bachelorās thesis - āā Effectivity of Mepilex Lite dressing in limitating skin side effects in vulvar cancer radiotherapyā. Within the framework of practical for research Lite silicone dressing use in ionasing induced skin damage restriction was inquired. The research was carried out qualitative and research instrument was observation protocol. The study raises a question of difference in ionising radiation treatment induced skin damage outcomes between groups, where one of them was using Mepilex Lite dressing for assasment of accuring compications and the other, controul group, where Mepilex Lite dressing was used for prophilaxis. Objective: evaluate Mepilex Lite effectivity regarding ionising radiation induced skin damage in prophylaxis for patients who are undergoing vulvar cancer radiation therapy. Summarization of the results of the study revieled, that while using Mepilex Lite silicone dressing for prophilactic purpose for patients, who undergo a vulvar cancer radiation therapy, ionazing induced skin damage is significally delayed
High salivary secretory IgA antibody levels are associated with less late-onset wheezing in IgE-sensitized infants
Low levels of secretory IgA (SIgA) and transient IgA deficiency have been associated with an increased risk for allergy, but data are conflicting. The aim was to assess the relationship between salivary SIgA antibody levels at 1 yr and wheezing at age four in a birth cohort, in particular the possible protective role of salivary SIgA in sensitized children. Saliva samples were obtained from all children (n = 67) with a positive skin prick test (SPT) at 1 yr and 212 children with a negative SPT. In all, 200 of these children responded to questionnaires at 4 yrs and 183 were skin prick tested at that age. The levels of salivary SIgA and salivary IgA antibodies to the most common food allergen egg and inhalant allergen cat were analyzed by ELISA. Serum was analyzed for IgE antibodies to egg and cat. Development of late-onset wheezing was associated with low SIgA levels in children with positive SPT to at least one allergen both at 1 and 4 yrs of age (p = 0.04), as well as in children with circulating IgE antibodies to egg or cat at 1 yr (p = 0.02). None of nine persistently sensitized children with SIgA levels in the upper quartile developed wheezing, when compared to 10/20 children with lower levels (p = 0.01). Older siblings, more than three infections during infancy, at least one smoking parent, and male gender, were all associated with SIgA in the upper quartile. In conclusion, high levels of SIgA antibodies in sensitized infants were associated with significantly less late-onset wheezing, supporting a protective role against development of asthmatic symptoms. Recurrent infections and other factors supporting an increased microbial pressure during infancy were associated with high levels of salivary SIgA.This is the authorsā version of:Anna Sandin, Bengt Bjorksten, Malin FagerĆ„s Bƶttcher, Erling Englund, Maria Jenmalm and Lennart Braback, High salivary secretory IgA antibody levels are associated with less late-onset wheezing in IgE-sensitized infants, 2011, Pediatric Allergy and Immunology, (22), 5, 477-481.http://dx.doi.org/10.1111/j.1399-3038.2010.01106.xCopyright: John Wiley and Sonshttp://www.wiley.com